miR-107 和 miR-126 与乳腺癌风险:病例对照研究

IF 1.1 4区 生物学 Q4 GENETICS & HEREDITY Genetic testing and molecular biomarkers Pub Date : 2024-04-01 Epub Date: 2024-03-15 DOI:10.1089/gtmb.2023.0606
Priyanka Gupta, Vasudha Sambyal, Jagmohan Singh Bali, Kamlesh Guleria, Manjit Singh Uppal, Meena Sudan
{"title":"miR-107 和 miR-126 与乳腺癌风险:病例对照研究","authors":"Priyanka Gupta, Vasudha Sambyal, Jagmohan Singh Bali, Kamlesh Guleria, Manjit Singh Uppal, Meena Sudan","doi":"10.1089/gtmb.2023.0606","DOIUrl":null,"url":null,"abstract":"<p><p><b><i>Background:</i></b> Micro RNAs are new diagnostic markers and therapeutic targets in breast cancer research. miR-107 and miR-126 have been reported to be linked with the pathogenesis of breast cancer. The present study investigates the levels of expression of miR-107 and miR-126 in patients with breast cancer to find their correlation with the risk of breast cancer in Amritsar, Punjab, Northwest India. <b><i>Material and Methods:</i></b> In total, 200 subjects, 100 patients with breast cancer and 100 controls, were enrolled to screen the expression of miR-107 and miR-126 using quantitative reverse transcription polymerase chain reaction (RT-PCR) technique. The Livak method (2<sup>-ΔΔCt</sup>) was used to calculate the fold change of the expression of micro RNAs. Student <i>t</i>-test was used to calculate the significant change in the expression of miRNAs in patients as compared with controls. Spearman rank correlation coefficient and ROC were conducted. The value of <i>p</i> < 0.05 was considered to indicate a statistically significant difference. <b><i>Results:</i></b> miR-107 was downregulated in patients with breast cancer as compared with controls (fold change = 0.467; <i>p</i> = 0.114) but not statistically significant. The expression of miR-126 was found to be 5.37 times elevated in patients with breast cancer, specifically in stage I and stage III patients (<i>p</i> = 0.009), compared with controls, which may indicate its oncogenic activity. The ROC analyses revealed that miR-126 could be a potential diagnostic marker. In conclusion oncogenic behavior of miR-126 is suggestive of its role in pathogenesis in patients with breast cancer.</p>","PeriodicalId":12603,"journal":{"name":"Genetic testing and molecular biomarkers","volume":null,"pages":null},"PeriodicalIF":1.1000,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"miR-107 and miR-126 and Risk of Breast Cancer: A Case-Control Study.\",\"authors\":\"Priyanka Gupta, Vasudha Sambyal, Jagmohan Singh Bali, Kamlesh Guleria, Manjit Singh Uppal, Meena Sudan\",\"doi\":\"10.1089/gtmb.2023.0606\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p><b><i>Background:</i></b> Micro RNAs are new diagnostic markers and therapeutic targets in breast cancer research. miR-107 and miR-126 have been reported to be linked with the pathogenesis of breast cancer. The present study investigates the levels of expression of miR-107 and miR-126 in patients with breast cancer to find their correlation with the risk of breast cancer in Amritsar, Punjab, Northwest India. <b><i>Material and Methods:</i></b> In total, 200 subjects, 100 patients with breast cancer and 100 controls, were enrolled to screen the expression of miR-107 and miR-126 using quantitative reverse transcription polymerase chain reaction (RT-PCR) technique. The Livak method (2<sup>-ΔΔCt</sup>) was used to calculate the fold change of the expression of micro RNAs. Student <i>t</i>-test was used to calculate the significant change in the expression of miRNAs in patients as compared with controls. Spearman rank correlation coefficient and ROC were conducted. The value of <i>p</i> < 0.05 was considered to indicate a statistically significant difference. <b><i>Results:</i></b> miR-107 was downregulated in patients with breast cancer as compared with controls (fold change = 0.467; <i>p</i> = 0.114) but not statistically significant. The expression of miR-126 was found to be 5.37 times elevated in patients with breast cancer, specifically in stage I and stage III patients (<i>p</i> = 0.009), compared with controls, which may indicate its oncogenic activity. The ROC analyses revealed that miR-126 could be a potential diagnostic marker. In conclusion oncogenic behavior of miR-126 is suggestive of its role in pathogenesis in patients with breast cancer.</p>\",\"PeriodicalId\":12603,\"journal\":{\"name\":\"Genetic testing and molecular biomarkers\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":1.1000,\"publicationDate\":\"2024-04-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Genetic testing and molecular biomarkers\",\"FirstCategoryId\":\"99\",\"ListUrlMain\":\"https://doi.org/10.1089/gtmb.2023.0606\",\"RegionNum\":4,\"RegionCategory\":\"生物学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/3/15 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q4\",\"JCRName\":\"GENETICS & HEREDITY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Genetic testing and molecular biomarkers","FirstCategoryId":"99","ListUrlMain":"https://doi.org/10.1089/gtmb.2023.0606","RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/3/15 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"GENETICS & HEREDITY","Score":null,"Total":0}
引用次数: 0

摘要

背景:据报道,miR-107 和 miR-126 与乳腺癌的发病机制有关。本研究调查了印度西北部旁遮普省阿姆利则市乳腺癌患者体内 miR-107 和 miR-126 的表达水平,以发现它们与乳腺癌风险的相关性。材料和方法:共招募了 200 名受试者(100 名乳腺癌患者和 100 名对照组),使用定量反转录聚合酶链反应(RT-PCR)技术筛查 miR-107 和 miR-126 的表达。采用 Livak 法(2-ΔΔCt)计算微 RNA 表达的折叠变化。采用学生 t 检验计算患者与对照组相比 miRNA 表达的显著变化。进行斯皮尔曼秩相关系数和 ROC 检验。p < 0.05 的值被认为表示差异有统计学意义。结果:与对照组相比,乳腺癌患者的 miR-107 表达下调(折叠变化 = 0.467; p = 0.114),但无统计学意义。与对照组相比,miR-126 在乳腺癌患者(尤其是 I 期和 III 期患者)中的表达量升高了 5.37 倍(p = 0.009),这可能表明其具有致癌活性。ROC 分析显示,miR-126 可能是一种潜在的诊断标志物。总之,miR-126 的致癌行为表明它在乳腺癌患者的发病机制中发挥作用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
miR-107 and miR-126 and Risk of Breast Cancer: A Case-Control Study.

Background: Micro RNAs are new diagnostic markers and therapeutic targets in breast cancer research. miR-107 and miR-126 have been reported to be linked with the pathogenesis of breast cancer. The present study investigates the levels of expression of miR-107 and miR-126 in patients with breast cancer to find their correlation with the risk of breast cancer in Amritsar, Punjab, Northwest India. Material and Methods: In total, 200 subjects, 100 patients with breast cancer and 100 controls, were enrolled to screen the expression of miR-107 and miR-126 using quantitative reverse transcription polymerase chain reaction (RT-PCR) technique. The Livak method (2-ΔΔCt) was used to calculate the fold change of the expression of micro RNAs. Student t-test was used to calculate the significant change in the expression of miRNAs in patients as compared with controls. Spearman rank correlation coefficient and ROC were conducted. The value of p < 0.05 was considered to indicate a statistically significant difference. Results: miR-107 was downregulated in patients with breast cancer as compared with controls (fold change = 0.467; p = 0.114) but not statistically significant. The expression of miR-126 was found to be 5.37 times elevated in patients with breast cancer, specifically in stage I and stage III patients (p = 0.009), compared with controls, which may indicate its oncogenic activity. The ROC analyses revealed that miR-126 could be a potential diagnostic marker. In conclusion oncogenic behavior of miR-126 is suggestive of its role in pathogenesis in patients with breast cancer.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
2.50
自引率
7.10%
发文量
63
审稿时长
1 months
期刊介绍: Genetic Testing and Molecular Biomarkers is the leading peer-reviewed journal covering all aspects of human genetic testing including molecular biomarkers. The Journal provides a forum for the development of new technology; the application of testing to decision making in an increasingly varied set of clinical situations; ethical, legal, social, and economic aspects of genetic testing; and issues concerning effective genetic counseling. This is the definitive resource for researchers, clinicians, and scientists who develop, perform, and interpret genetic tests and their results. Genetic Testing and Molecular Biomarkers coverage includes: -Diagnosis across the life span- Risk assessment- Carrier detection in individuals, couples, and populations- Novel methods and new instrumentation for genetic testing- Results of molecular, biochemical, and cytogenetic testing- Genetic counseling
期刊最新文献
Immune Regulatory Circular RNAs, circRasGEF1B and circHIPK3, Are Upregulated in Peripheral Blood Mononuclear Cells of COVID-19 Patients. Association of ANRIL Gene Polymorphisms with Gastric Cancer Risk: A Case-Control Study. Evaluation of Multigene Methylation for Blood-Based Detection of Colorectal Cancer. Human Leukocyte Antigen-G Gene Polymorphism in Peninsular Malaysia: A Preliminary Report. Analysis of ANO6, HAPLN1, and EDIL3 Polymorphisms in Patients with Ankylosing Spondylitis in a Chinese Han Population: A Case-Control Study.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1